Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
ORG Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 108.2% ...
International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...
In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...
Vertex Pharmaceuticals Incorporated (VRTX ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With headquarters in the heart of Chicago's financial district ...
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective cut by Wells Fargo & Company from $555.00 to ...
The increasing adoption of e-invoicing globally and the ongoing enterprise resource planning (ERP) migration super cycle present multi-year growth opportunities for Vertex. As companies shift to ...
Vertex, Inc. (NASDAQ:VERX – Get Free Report)’s stock price fell 4.7% on Friday .The stock traded as low as $50.56 and last traded at $50.70. 428,997 shares traded hands during mid-day trading ...